Fladrafinil vs Modafinil

Fladrafinil wins for sheer potency (active at much lower doses), ease of sourcing as a research chemical, and lower pill burden. It is also uniquely noted for an anti-aggressive effect, which is distinct from other eugeroics in this class.

Modafinil wins for proven track record, well-characterized safety profile, official pharmaceutical formulations, and known pharmacokinetics. For users prioritizing reproducibility, minimal risk, and tight control over dose-response, modafinil is the reference standard.

Pick Fladrafinil if:

• Research protocols require eugeroic effects at lower dosages or when pill burden is a concern.
• Modafinil is not accessible due to sourcing restrictions and RC sourcing is on the table.
• The protocol specifically benefits from the anti-aggressive profile unique to fladrafinil.
• Rapid onset and stronger subjective effects are desired (e.g., for acute shift resets).
• Exploring alternative dopamine transporter inhibitors with a distinct metabolic route (prodrug to modafinil family but different liver enzyme profile).

Pick Modafinil if:

• The protocol demands established safety and pharmacological data over decades of use.
• Consistency across cycles is critical; pharmaceutical-grade supply is preferred.
• Subject tolerability and long-term safety are prioritized (especially for longer cycles or repeated use).
• Appetite suppression and wakefulness are needed for cutting, shift work, or contest prep scenarios.
• Avoiding unexplored metabolites or side-effect profiles is essential for the research application.